Can Adding Ribociclib to Hormone Therapy Improve Breast Cancer Outcomes

In patients with breast cancer combination therapy had increased invasive disease-free survival compared to those who were treated with the hormone therapy alone.

Addition of ribociclib, the targeted therapy medication to hormone therapy was found to show invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer (). The addition of the targeted therapy reduced the risk of recurrence by 25%.

The results were shared today during the American Society of Clinical Oncology Annual Meeting by Dr. Dennis Slamon, chair of hematology-oncology and director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center.

Screening for Breast Cancer with Clinical Breast Examination
Clinical breast examination is a simple and inexpensive method of detecting breast cancer especially in women who do not have access to mammography.

‘Combination treatments for patients with stage 2 or stage 3 HR positive/HER2 negative breast cancer were found to show promising results. #breastcancer #breastcancertreatment #womenbreastcancer’

What is HR Positive/HER2 Negative Breast Cancer

HR positive/HER2 negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States.

Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer.

Slamon also led the discovery program that found that cyclin-dependent kinase inhibitors are effective in treating hormone receptor positive breast cancer. These drugs work by blocking the activity of cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.

Quiz on Breast Cancer
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a woman who breast-feeds is at a lower risk of developing cancer compared to another who does not .Are these mere old wives tales or is there some truth in it? This quiz on breast cancer has all the details.

This work ultimately helped lead to the FDA approval of ribociclib and other related drugs to treat metastatic breast cancer. There are now three CDK4/6 inhibitors that have been approved by the FDA for combination treatment with standard hormone therapies in the metastatic setting.

Building on this past research, the team assessed whether the treatment combination could also improve outcomes in early breast cancer.

Breast Cancer Risk Assessment Calculator
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast cancer facts and more information on signs and symptoms of breast cancer and mammography.

The clinical trial, called NATALEE, involved 5101 patients with stage 2 or stage 3 early HR positive/HER2 negative breast cancer. Patients were randomized into two arms: 2549 were randomized to the combination treatment and 2552 to the hormone therapy alone. Invasive disease-free survival was the primary endpoint of the study ().

The median duration on study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20% and 57% patients respectively. Invasive disease-free survival was evaluated after 426 events.

Hereditary Breast and Ovarian Cancer
Have a history of cancers running in the family? It may be the genes. Find out your risk of developing hereditary breast, ovary, prostate, pancreatic and skin cancers.

At the time of this analysis, 189 people in the ribociclib group (7.4% of patients) experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group (9.3% of patients). The data showed a statistically significant improvement in the risk of invasive disease in favor of the combination arm.

The invasive disease-free survival rates at three years were 90.4%, compared to 87.1% for women who were treated with only hormone therapy.

Ribociclib at 400 mg had a favorable safety profile with no new signals.

“Overall, the combination therapy showed more favorable outcomes, significantly reducing the risk of the cancer returning,” Slamon said. “These results should change how we evaluate and treat patients.”

The study was sponsored by Novartis, which developed ribociclib at the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.

References:

ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer - (https://www.uclahealth.org/news/asco-adding-ribociclib-hormone-therapy-improves-outcomes)
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) - (https://clinicaltrials.gov/ct2/show/NCT03701334)

Source-Eurekalert